Emergent BioSolutions | EBS - Devedores Comerciais





Devedores Comerciais Alterar Data
Acadia Pharmaceuticals USD 148.38M 153K 2026-03
Akebia Therapeutics USD 47.03M 19.19M 2025-12
ALKERMES USD 456.48M 48.85M 2026-06
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Amarin USD 126.83M 477K 2025-12
ANI Pharmaceuticals USD 255.43M 25.65M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Coherus Biosciences USD 18.42M 232.08M 2025-12
Emergent BioSolutions USD 290.1M 134.2M 2023-06
Exelixis USD 328.95M 42.03M 2026-03
Glaxosmithkline GBP 10.49B 40.6M 2026-03
Heron Therapeutics USD 89.59M 8.54M 2025-12
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
Ironwood Pharmaceuticals USD 81.89M 5.68M 2024-12
Lexicon Pharmaceuticals USD 2.38M 50K 2025-12
Lonza CHF 1.78B 55M 2025-12
Merck USD 11.78B 345M 2025-12
Moderna USD 17M 54M 2026-06
Myriad Genetics USD 115.3M 2.7M 2025-12
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 887M 118.9M 2026-06
Pacira USD 125.64M 1.57M 2026-03
Pfizer USD 16.17B 332M 2026-03
PTC Therapeutics USD 219.92M 38.3M 2026-03
Sanofi EUR 492M 10M 2026-06
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
United Therapeutics USD 312M 38.2M 2026-03
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12